WHO R&D Blueprint

WHO R&D Blueprint
Name	WHO R&D Blueprint
Formation	2015
Purpose	To accelerate R&D for epidemic threats
Headquarters	Geneva
Parent organization	World Health Organization

WHO R&D Blueprint. The WHO R&D Blueprint is a global strategy and preparedness plan developed by the World Health Organization to dramatically accelerate research and development during epidemics. Established in the wake of the 2014-2016 Ebola outbreak in West Africa, it aims to fast-track the availability of effective tests, vaccines, and medicines. The initiative fosters coordinated action among scientists, public health agencies, regulatory authorities, and funders to prepare for and respond to Disease X and other priority pathogens.

Background and establishment

The blueprint was formally launched by the World Health Organization in 2015, following critical lessons learned from the delayed response to the 2014-2016 Ebola outbreak in West Africa. That crisis exposed severe gaps in the global health system, particularly the lack of ready-to-deploy medical countermeasures. Key reports, including from the WHO Ebola Interim Assessment Panel and the United Nations High-Level Panel on the Global Response to Health Crises, underscored the urgent need for a coordinated R&D framework. The initiative was endorsed during the World Health Assembly and built upon earlier efforts like the 2009 H1N1 influenza pandemic response, aiming to transform ad hoc efforts into a systematic, pre-planned approach for future outbreaks.

Objectives and scope

The primary objective is to reduce the time between the declaration of a public health emergency of international concern and the availability of effective medical products. Its scope encompasses the entire research and development pipeline, from basic science and epidemiology to clinical trials, regulatory approval, and equitable access. A core focus is fostering rapid data and sample sharing across borders, standardizing clinical trial protocols, and creating pre-negotiated contractual and funding mechanisms. The blueprint specifically targets pathogens with epidemic or pandemic potential that lack sufficient countermeasures, operating as a complement to broader frameworks like the International Health Regulations.

Priority diseases and pathogens

A list of priority diseases is regularly reviewed by an independent panel of experts using a specialized WHO tool. The initial list, created in 2015, included known threats such as Ebola virus disease, Middle East respiratory syndrome coronavirus, and Severe Acute Respiratory Syndrome. Following the COVID-19 pandemic, SARS-CoV-2 was added. The list also includes the conceptual Disease X, representing a known or unknown pathogen capable of causing a serious international epidemic. Other pathogens frequently featured are Lassa fever, Nipah virus, Zika virus, and Crimean-Congo haemorrhagic fever. This dynamic list guides global investment and preparedness activities.

Research and development initiatives

The blueprint activates coordinated R&D roadmaps for each priority disease, outlining critical knowledge gaps and product development goals. It has spurred initiatives like the Coalition for Epidemic Preparedness Innovations, which funds vaccine development for emerging infectious diseases. During active outbreaks, such as the Kivu Ebola epidemic or the COVID-19 pandemic, it facilitates the Solidarity Trial for therapeutics and establishes core protocols. The blueprint also supports the development of platform technologies, like messenger RNA vaccine platforms, that can be rapidly adapted for new pathogens, and maintains a blueprint of candidate vaccines and therapeutics under evaluation.

Implementation and coordination

Implementation relies on a vast network of partners coordinated by the World Health Organization headquarters in Geneva. This includes close collaboration with academia, biotechnology firms, pharmaceutical companies, entities like Gavi, the Vaccine Alliance and the Global Fund, and major funders such as the European Commission and the Wellcome Trust. The blueprint promotes the establishment of pre-positioned clinical trial networks, like the WHO-led clinical trial network, and works with regulators through the International Coalition of Medicines Regulatory Authorities to align on approval pathways. Coordination ensures that efforts from Africa CDC to the United States Department of Health and Human Services are synergistic.

Impact and evaluation

The blueprint's impact was tested and demonstrated during the COVID-19 pandemic, where its prior work on coronavirus research and platform technologies contributed to the unprecedented speed of vaccine development. It has established new norms for rapid data sharing, as seen with the Global Initiative on Sharing All Influenza Data for SARS-CoV-2 sequences. Evaluations, including by the WHO Independent Advisory and Monitoring Committee, have highlighted successes in coordination but also challenges in ensuring equitable access to products. The experience has informed subsequent strategies, including a broader WHO strategy on research for health and the proposed pandemic accord, aiming to institutionalize the blueprint's principles for future global health security.

Category:World Health Organization Category:Public health Category:Epidemiology Category:Medical research